Highlights and Quick Summary
- Income from Continuous Operations for the quarter ending March 31, 2022 was $-31.5 Million (a 360.99% increase compared to previous quarter)
- Year-over-year quarterly Income from Continuous Operations increased by 317.89%
- Annual Income from Continuous Operations for 2021 was $40.1 Million (a -369.26% decrease from previous year)
- Annual Income from Continuous Operations for 2020 was $-14.9 Million (a 80.51% increase from previous year)
- Annual Income from Continuous Operations for 2019 was $-8.24 Million (a -21.4% decrease from previous year)
- Twelve month Income from Continuous Operations ending March 31, 2022 was $-51.8 Million (a 96.73% increase compared to previous quarter)
- Twelve month trailing Income from Continuous Operations increased by 75.9% year-over-year
Trailing Income from Continuous Operations for the last four month:
31 Mar '22 | 30 Sep '21 | 31 Mar '21 | 30 Sep '20 |
---|---|---|---|
$-51.8 Million | $-26.3 Million | $-32.3 Million | $-29.4 Million |
Visit stockrow.com/BFAGY
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Income from Continuous Operations of Biofrontera AG Sponsored ADR
Most recent Income from Continuous Operationsof BFAGY including historical data for past 10 years.Interactive Chart of Income from Continuous Operations of Biofrontera AG Sponsored ADR
Biofrontera AG Sponsored ADR Income from Continuous Operations for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2022 | – | – | – | $-31.53 | – |
2021 | – | – | $-6.84 | $-5.88 | $40.06 |
2020 | – | – | $-7.55 | $-6.06 | $-14.88 |
2019 | – | – | $-12.84 | $-3.0 | $-8.24 |
2018 | – | – | – | $-5.31 | $-10.48 |
2017 | – | – | $-6.91 | $-3.74 | $-18.2 |
2016 | $-3.85 | – | – | – | $-11.71 |
Business Profile of Biofrontera AG Sponsored ADR
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic